ArticleTranslational andrology and urology2024
Relative fat mass is a valuable predictor of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: clinical implications.
Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between relative fat mass and colorectal cancer: a cross-sectional study.Frontiers in nutrition · 2025Article
- Risk factors for benign prostatic hyperplasia: a comprehensive review.Revista da Associacao Medica Brasileira (1992) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global prevalence of lower urinary tract symptoms suggestive of benign prostate hyperplasia (LUTS/BPH) escalates, with obesity recognized as a major contributing factor. However, the association between the relative fat mass (RFM) and LUTS/BPH remains unexplored. This 7-year follow-up study aimed to investigate the cross-sectional and longitudinal relationships between RFM and LUTS/BPH. Methods: Based on the China Health and Retirement Longitudinal Study (CHARLS) data, we interpolated missing values of covariates using multivariate imputation via chained equations grounded on the random forest method. Stratifying participants by tertiles of RFM, we employed multivariate binary logistic and restricted cubic spline (RCS) regressions to assess the odds ratio (OR) and dose-response relationship between RFM and LUTS/BPH. Subgroup and interactive analyses assessed covariate impacts. Sensitivity analysis involved stratifying RFM by median and quartiles and excluding males aged ≤60 years to confirm model robustness. A retrospective cohort [2011-2018] was used to investigate longitudinal associations, with additional cohorts [2011-2013, 2011-2015] for further sensitivity checks. Results: A total of 6,253 males aged over 40 years were included in the 2011 baseline survey, with 4,321 observed in the 2018 follow-up. The final model revealed a positive correlation between high RFM and prevalent LUTS/BPH. Specifically, the risk for the third tertile group increased by a factor of 1.47 [95% confidence interval (CI): 1.16-1.87; P=0.001]. No significant interactive effects were observed. Linear trends were confirmed by RCS regression across demographics (P for overall <0.05). In the 2011-2018 cohort, the final model linked high RFM to a 1.41 times higher incidence of LUTS/BPH (95% CI: 1.11-1.80; P=0.003) in the third tertile subgroup. All sensitivity analyses consistently affirmed these positive associations. Conclusions: Positive cross-sectional and longitudinal associations between RFM and LUTS/BPH were observed, underscoring RFM's potential as a valuable predictor for prompt detection targeting LUTS/BPH in aging males. Consequently, early management and treatment strategies could be implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.